Literature DB >> 35604622

Choroidal structural alterations in diabetic patients in association with disease duration, HbA1c level, and presence of retinopathy.

Emine Temel1, Gökçen Özcan2, Özge Yanık2, Sibel Demirel2, Figen Batıoğlu2, İrem Kar3, Emin Özmert2.   

Abstract

PURPOSE: To assess choroidal structural changes in diabetic patients in association with disease duration, HbA1c level, and presence of retinopathy.
METHODS: This retrospective cross-sectional study included treatment-naive patients with non-proliferative DR (NPDR) (group 1), diabetic patients without DR (group 2), and healthy subjects (group 3). Patients were also grouped according to the duration of diabetes: long-term group (> 15 years, n = 32) and short-term group (˂ 15 years, n = 28). The choroidal thickness was measured at three points; subfoveal, 1500 μm nasal, and 1500 μm temporal to the fovea. The choroidal area, stromal area, luminal area (LA), and choroidal vascularity index (CVI) were quantified using ImageJ. Partial correlation analysis and one-way analysis of covariance test were performed for statistical analysis.
RESULTS: The study included 30 eyes of 30 treatment-naive patients with NPDR (group 1), 30 eyes of 30 diabetic patients without DR (group 2), and 30 eyes of 30 healthy persons (group 3). The mean subfoveal, nasal, and temporal choroidal thicknesses were decreased in group 1 in comparison with controls (p < 0.001, p = 0.035, and p = 0.005, respectively). The mean LA in group 1 and group 2 were both significantly lower compared to group 3 (group 1 vs. group 3, p = 0.004; group 2 vs. group 3, p = 0.020). CVI was significantly lower in group 1 and group 2 than in controls (group 1 vs. group 3, p = 0.019; group 2 vs. group 3, p = 0.025). CVI was significantly lower in the long-duration group than in the short-duration group (p < 0.001). A moderate negative correlation was found between the duration of diabetes and CVI (r = - 0.467, p < 0.001). A moderate negative correlation was found between HbA1c level and luminal area and CVI (r = - 0.466, p < 0.001, and r = - 0.425, p < 0.001, respectively).
CONCLUSION: Choroidal structure and CVI are altered even in the absence of clinically confirmed retinopathy and these alterations are related to the duration of diabetes.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  Choroidal thickness; Choroidal vascularity index; Diabetes mellitus; Diabetic retinopathy; Enhanced depth imaging optical coherence tomography; HbA1c

Year:  2022        PMID: 35604622     DOI: 10.1007/s10792-022-02363-w

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  29 in total

Review 1.  Diabetic retinopathy.

Authors:  David A Antonetti; Ronald Klein; Thomas W Gardner
Journal:  N Engl J Med       Date:  2012-03-29       Impact factor: 91.245

2.  Enhanced depth imaging spectral-domain optical coherence tomography.

Authors:  Richard F Spaide; Hideki Koizumi; Maria C Pozzoni; Maria C Pozonni
Journal:  Am J Ophthalmol       Date:  2008-07-17       Impact factor: 5.258

Review 3.  Diabetic choroidopathy: a review of the current literature.

Authors:  Diana Melancia; André Vicente; João Paulo Cunha; Luís Abegão Pinto; Joana Ferreira
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-04-25       Impact factor: 3.117

Review 4.  Global Estimates on the Number of People Blind or Visually Impaired by Diabetic Retinopathy: A Meta-analysis From 1990 to 2010.

Authors:  Janet L Leasher; Rupert R A Bourne; Seth R Flaxman; Jost B Jonas; Jill Keeffe; Kovin Naidoo; Konrad Pesudovs; Holly Price; Richard A White; Tien Y Wong; Serge Resnikoff; Hugh R Taylor
Journal:  Diabetes Care       Date:  2016-09       Impact factor: 19.112

5.  The prevalence of diabetic retinopathy among adults in the United States.

Authors:  John H Kempen; Benita J O'Colmain; M Cristina Leske; Steven M Haffner; Ronald Klein; Scot E Moss; Hugh R Taylor; Richard F Hamman
Journal:  Arch Ophthalmol       Date:  2004-04

6.  Reduced ocular blood flow as an early indicator of diabetic retinopathy in a mouse model of diabetes.

Authors:  Eric R Muir; René C Rentería; Timothy Q Duong
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-09-21       Impact factor: 4.799

7.  Diabetic retinopathy in a multi-ethnic cohort in the United States.

Authors:  Tien Yin Wong; Ronald Klein; F M Amirul Islam; Mary Frances Cotch; Aaron R Folsom; Barbara E K Klein; A Richey Sharrett; Steven Shea
Journal:  Am J Ophthalmol       Date:  2006-03       Impact factor: 5.258

Review 8.  Viewing the choroid: where we stand, challenges and contradictions in diabetic retinopathy and diabetic macular oedema.

Authors:  António Campos; Elisa J Campos; João Martins; António Francisco Ambrósio; Rufino Silva
Journal:  Acta Ophthalmol       Date:  2016-08-22       Impact factor: 3.761

9.  Prevalence and risk factors for diabetic retinopathy: the Korea National Health and Nutrition Examination Survey 2008-2011.

Authors:  Donghyun Jee; Won Ki Lee; Seungbum Kang
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-10-17       Impact factor: 4.799

Review 10.  Global prevalence and major risk factors of diabetic retinopathy.

Authors:  Joanne W Y Yau; Sophie L Rogers; Ryo Kawasaki; Ecosse L Lamoureux; Jonathan W Kowalski; Toke Bek; Shih-Jen Chen; Jacqueline M Dekker; Astrid Fletcher; Jakob Grauslund; Steven Haffner; Richard F Hamman; M Kamran Ikram; Takamasa Kayama; Barbara E K Klein; Ronald Klein; Sannapaneni Krishnaiah; Korapat Mayurasakorn; Joseph P O'Hare; Trevor J Orchard; Massimo Porta; Mohan Rema; Monique S Roy; Tarun Sharma; Jonathan Shaw; Hugh Taylor; James M Tielsch; Rohit Varma; Jie Jin Wang; Ningli Wang; Sheila West; Liang Xu; Miho Yasuda; Xinzhi Zhang; Paul Mitchell; Tien Y Wong
Journal:  Diabetes Care       Date:  2012-02-01       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.